DEF: Phio Pharmaceuticals Seeks Shareholder Approval for Expanded Incentive Plan Amidst Going Concern Warning

Phio Pharmaceuticals Corp. is seeking shareholder approval for key corporate governance matters, including the election of directors and a significant increase in its equity incentive plan, while facing a 'going concern' warning from its auditors.

Summary

• Shareholders are invited to the 2025 Annual Meeting on September 11, 2025, to vote on six proposals, including director elections and an amendment to the 2020 Long Term Incentive Plan.
• The company proposes to increase the number of shares available for issuance under its 2020 Long Term Incentive Plan by 950,000, bringing the total to 950,891 shares, representing approximately 19.8% of current outstanding common stock.
• The Board of Directors unanimously recommends voting FOR the election of all six director nominees, the ratification of Grant Thornton, LLP as the independent auditor, the amendment to the incentive plan, and the advisory vote on executive compensation.
• The Board recommends a 'THREE YEARS' frequency for future advisory votes on executive compensation.
• Robert J. Bitterman's salary was voluntarily reduced by $100,000 effective October 16, 2023, and restored to its original amount of $440,000 in April 2025.
• Robert M. Infarinato transitioned from Vice President and Chief Financial Officer to VP, Strategic Development effective June 6, 2025, and is no longer an executive officer.
• The company reported net losses of $(7,150) thousand in 2024, $(10,826) thousand in 2023, and $(11,480) thousand in 2022.
• The independent registered public accounting firm, BDO USA, P.C., included an explanatory paragraph in its reports for fiscal years ended December 31, 2024, and 2023, relating to substantial doubt about the company's ability to continue as a going concern.
• BDO USA, P.C. was dismissed as the independent auditor on April 17, 2025, and Grant Thornton, LLP was engaged on the same date for the fiscal year ending December 31, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to persistent net losses and the explicit 'going concern' warning from the auditor, which overshadows the routine corporate governance updates and efforts to align management incentives. The significant proposed dilution for the incentive plan also contributes to negative sentiment.

Positives

• The Board of Directors has adopted an Incentive Compensation Recovery Policy (clawback policy) as required by SEC rules, promoting accountability.
• The company has a Code of Ethics and Conduct and an Insider Trading Policy, prohibiting pledging or hedging of company securities, indicating strong governance practices.
• The Board has a Lead Independent Director and all committee members are independent, enhancing oversight.
• The modification of unvested RSU vesting terms from 3 years to 1 year on September 11, 2024, could improve talent retention and motivation.

Negatives

• The proposed increase of 950,000 shares for the incentive plan represents approximately 19.8% dilution to current stockholders.
• The company has consistently reported net losses, with $(7,150) thousand in 2024, $(10,826) thousand in 2023, and $(11,480) thousand in 2022.
• Named executive officers did not receive any annual incentive bonus payments in 2024 or 2023, suggesting corporate performance goals were not met or bonuses were not awarded.
• The company's total shareholder return has been negative, with a $100 investment on December 31, 2022, valued at $23.25 by the end of 2024.

Risks

• The independent auditor's reports for fiscal years 2024 and 2023 included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• The proposed increase in shares for the incentive plan could lead to significant dilution for existing shareholders.
• Broker non-votes, especially with large brokerage firms eliminating discretionary voting for routine matters, may make it increasingly difficult to obtain the majority voting power necessary to pass certain routine matters.

Future Outlook

The company anticipates the additional 950,000 shares under the 2020 Long Term Incentive Plan will be sufficient to fund its equity compensation needs for approximately 1-2 years. The Board intends to consider the results of the advisory vote on executive compensation when making future decisions and will evaluate the frequency of future Say-on-Pay votes based on stockholder preference, though it recommends a three-year frequency.

Management Comments

• Robert Bitterman, President and Chief Executive Officer, stated, 'We are pleased to make use of the Securities and Exchange Commission (the SEC) rules that allow companies to furnish proxy materials to their stockholders via the internet. We believe the ability to deliver proxy materials electronically allows us to provide our stockholders with the information they need, while lowering the costs of delivery and reducing the environmental impact from the distribution of our Annual Meeting materials. We look forward to seeing you at the Annual Meeting.'

Industry Context

The filing is a standard proxy statement for an annual meeting, common across publicly traded companies. The proposed increase in the equity incentive plan is a typical mechanism for biotechnology companies like Phio Pharmaceuticals to attract and retain talent, especially given the long development cycles and high-risk nature of the industry. The 'going concern' warning is a significant red flag, often seen in early-stage or struggling biotech firms that rely heavily on external funding for R&D and operations.

Comparison to Industry Standards

• The proposed 19.8% dilution from the increased share pool for the incentive plan is on the higher side compared to typical annual equity grants in the biotech industry, which often aim to keep dilution below 10-15% over a multi-year period, though it's for a 1-2 year funding horizon.
• The three-year average burn rate of approximately 4% is within acceptable ranges for many growth-oriented biotech companies, indicating a moderate pace of equity award issuance relative to outstanding shares.
• An overhang of 15% (post-approval) is relatively high for the industry, as institutional investors and proxy advisory firms often prefer overhangs below 10-15% to limit potential dilution.
• The 'going concern' qualification from the auditor is a critical indicator of financial distress, a common challenge for clinical-stage biotechnology companies that have not yet achieved commercial revenue, but it places the company in a higher risk category compared to more established or revenue-generating peers.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from the proposed increase in the equity incentive plan and are directly impacted by the 'going concern' warning, indicating significant financial risk. Their votes are crucial for corporate governance matters.
• Employees and Management: The expanded incentive plan and modified RSU vesting terms are designed to attract, retain, and motivate key personnel, aligning their interests with company success.
• Creditors: The 'going concern' warning signals increased risk, which could affect the company's ability to secure future financing or impact existing debt terms.

Next Steps

• The 2025 Annual Meeting of Stockholders will be held on September 11, 2025, where shareholders will vote on the proposed matters.
• The Board will consider the results of the advisory vote on executive compensation when considering future decisions related to such proposal.
• The Board will consider the outcome of the advisory vote on the frequency of Say-on-Pay votes when determining the frequency of future advisory votes on executive compensation.

Key Dates

Recommendation

The company faces significant financial challenges, evidenced by consistent net losses and a 'going concern' warning from its auditors. This indicates high operational risk and uncertainty regarding its long-term viability. While efforts to align management incentives through an expanded equity plan are positive for talent retention, the associated dilution and the underlying financial distress make the stock a speculative investment. A 'hold' recommendation is appropriate for existing investors who may wish to monitor the company's progress on its clinical programs and financial stability, but new investment is not advised given the substantial risks.

Keywords

Pharmaceuticals, Biotechnology, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Equity Incentive Plan, Shareholder Meeting, Going Concern, Dilution, Board of Directors